Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 31Pancreatic Fistula 4Pancreatic Ductal Adenocarcinoma 2Jaundice, Obstructive 2Gastroparesis 2Recurrence 1Peritoneal Diseases 1Periampullary Cancer 1Pancreatitis, Chronic 1Pancreatic Adenocarcinoma 1Obesity 1Non-alcoholic Fatty Liver Disease 1Neoplasm Metastasis 1Metabolic Syndrome 1Locally Advanced Pancreatic Adenocarcinoma 1Hypoxia 1Hemorrhage 1Gastrointestinal Stromal Tumor of Duodenum 1Fatty Liver 1Diabetes Mellitus 1Cholangiocarcinoma 1Carcinoma, Pancreatic Ductal 1Bile Duct Neoplasms 1

Interventions

Hyperthermic Intraperitoneal Chemotherapy 2Tissue Banks 1Pancreaticoduodenectomy 1Paclitaxel 1Mitomycin 1Gemcitabine 1Food, Formulated 1Filgrastim 1Carboplatin 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Peritoneal Diseases × Pancreaticoduodenectomy × Clear all
NCT02850874 2022-04-27

HIPEC as Neoadjuvant Treatment for Resectable Pancreatic Adenocarcinoma

Wake Forest University Health Sciences

Phase 2 Withdrawn
Gastrointestinal

Pancreatic Neoplasms, Peritoneal Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡